Free tool
FAERS Monitor: Rogaine (For Women)
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019501 or its brand name (Rogaine (For Women), Minoxidil). Reports on generic versions are filed under their own applications.
Reports
44,887
Serious
4,801
11% of reports
Hospitalization
2,105
Death reported
454
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- adverse drug reaction8,621
- drug ineffective7,781
- alopecia3,745
- application site pruritus2,976
- off label use2,224
- application site irritation1,441
- application site pain1,432
- overdose1,413
- hair texture abnormal1,402
- headache1,355
- incorrect dose administered1,331
- inappropriate schedule of product administration1,196
- wrong technique in product usage process1,183
- product use in unapproved indication1,150
- pruritus1,002
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 95 |
| 2005 | 122 |
| 2006 | 128 |
| 2007 | 89 |
| 2008 | 113 |
| 2009 | 130 |
| 2010 | 149 |
| 2011 | 167 |
| 2012 | 219 |
| 2013 | 152 |
| 2014 | 196 |
| 2015 | 2,015 |
| 2016 | 2,755 |
| 2017 | 2,715 |
| 2018 | 2,301 |
| 2019 | 2,081 |
| 2020 | 3,225 |
| 2021 | 5,591 |
| 2022 | 8,463 |
| 2023 | 6,201 |
| 2024 | 3,687 |
| 2025 | 2,671 |
| 2026 | 1,622 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,009,272 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| application site pruritusSignal | 2,976 | 70.6 | 68.0 | 177,519 |
| application site irritationSignal | 1,441 | 61.2 | 58.0 | 75,496 |
| hair texture abnormalSignal | 1,402 | 54.7 | 51.8 | 66,214 |
| adverse drug reactionSignal | 8,621 | 49.6 | 48.6 | 373,016 |
| application site painSignal | 1,432 | 32.5 | 30.8 | 40,904 |
| alopeciaSignal | 3,745 | 9.1 | 8.8 | 26,691 |
| inappropriate schedule of product administrationSignal | 1,196 | 3.1 | 3.0 | 1,728 |
| overdoseSignal | 1,413 | 3.1 | 2.9 | 1,994 |
| drug ineffectiveSignal | 7,781 | 2.8 | 2.7 | 9,381 |
| wrong technique in product usage processSignal | 1,183 | 2.7 | 2.6 | 1,316 |
| incorrect dose administeredSignal | 1,331 | 2.7 | 2.6 | 1,479 |
| product use in unapproved indicationSignal | 1,150 | 2.2 | 2.1 | 738 |
| pruritus | 1,002 | 1.2 | 1.1 | 41 |
| off label use | 2,224 | 1.2 | 1.1 | 70 |
| headache | 1,355 | 1.0 | 1.0 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.